EFPIA statement on Brexit
24.02.16
As part of the EU, UK pharmaceutical companies can continue to benefit from pan-European collaborations in research and development, the EU marketplace, EU advocacy on global trade issues and a harmonised regulatory environment.
Pharmaceutical companies across Europe face considerable uncertainty at the prospect of the UK leaving the EU. Brexit has the potential to impact on regulation, the status of the EMA, finance, employment, the transfer of personal data and the European research ecosystem.
The decision to leave or remain within the EU is a decision for UK citizens, however, EFPIA firmly believes that the UK’s continued membership of the EU is in the best interests of a strong life sciences sector in the UK and Europe.